"Klinick\u00E1 onkologie" . "6" . . . "0862-495X" . "Targeted bio logic therapy has been proven to be effective compared to the current therapy of metastatic renal cell carcinoma (mRCC) in clinical studies as well as in actual clinical practice, but its high cost is a potentially limiting factor. Since the local cost-effectiveness analysis is missing, we assessed the cost of sunitinib and sorafenib in the treatment of mRCC in a comprehensive cancer centre."@en . . . "[935309CA35BC]" . "Kom\u00EDnek, Ji\u0159\u00ED" . "S" . "Demlov\u00E1, Regina" . "CZ - \u010Cesk\u00E1 republika" . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledviny"@cs . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledviny"@cs . . "Economic Evaluation of Targeted Biologic Therapy in Metastatic Renal Cell Carcinoma"@en . "7"^^ . . "3"^^ . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledviny" . "Ondr\u00E1\u010Dkov\u00E1, Barbora" . . "RIV/00216224:14110/10:00045949" . "2"^^ . . . . . . . "V l\u00E9\u010Db\u011B pokro\u010Dil\u00E9ho karcinomu ledvin se v posledn\u00EDch letech za\u010Dala vyu\u017E\u00EDvat c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba, kter\u00E1 prok\u00E1zala svou \u00FA\u010Dinnost v \u0159ad\u011B klinick\u00FDch studi\u00ED i v re\u00E1ln\u00E9 klinick\u00E9 praxi. Ur\u010Ditou limitac\u00ED jejich pod\u00E1n\u00ED v\u0161ak z\u016Fst\u00E1v\u00E1 vysok\u00E1 finan\u010Dn\u00ED n\u00E1ro\u010Dnost. P\u0159esn\u00E1 data pro stanoven\u00ED n\u00E1kladov\u00E9 efektivity v \u010CR dosud chyb\u011Bj\u00ED, pokusili jsme se proto zhodnotit celkov\u00E9 n\u00E1klady na terapii mRCC v komplexn\u00EDm onkologick\u00E9m centru u pacient\u016F l\u00E9\u010Den\u00FDch sunitinibem a/ nebo sorafenibem." . "23" . "Anal\u00FDza n\u00E1klad\u016F na c\u00EDlenou biologickou l\u00E9\u010Dbu pacient\u016F s metastatick\u00FDm karcinomem ledviny" . . "pharmacoeconomics; targeted therapy; sunitinib; sorafenib; renal cell carcinoma"@en . "RIV/00216224:14110/10:00045949!RIV11-MSM-14110___" . . "14110" . "Economic Evaluation of Targeted Biologic Therapy in Metastatic Renal Cell Carcinoma"@en . "V l\u00E9\u010Db\u011B pokro\u010Dil\u00E9ho karcinomu ledvin se v posledn\u00EDch letech za\u010Dala vyu\u017E\u00EDvat c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba, kter\u00E1 prok\u00E1zala svou \u00FA\u010Dinnost v \u0159ad\u011B klinick\u00FDch studi\u00ED i v re\u00E1ln\u00E9 klinick\u00E9 praxi. Ur\u010Ditou limitac\u00ED jejich pod\u00E1n\u00ED v\u0161ak z\u016Fst\u00E1v\u00E1 vysok\u00E1 finan\u010Dn\u00ED n\u00E1ro\u010Dnost. P\u0159esn\u00E1 data pro stanoven\u00ED n\u00E1kladov\u00E9 efektivity v \u010CR dosud chyb\u011Bj\u00ED, pokusili jsme se proto zhodnotit celkov\u00E9 n\u00E1klady na terapii mRCC v komplexn\u00EDm onkologick\u00E9m centru u pacient\u016F l\u00E9\u010Den\u00FDch sunitinibem a/ nebo sorafenibem."@cs . "246691" . . .